Argenx
ARGX
#397
Rank
NZ$108.81 B
Marketcap
NZ$1,739
Share price
0.16%
Change (1 day)
50.62%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$26.45. In 2025 the company made an earnings per share (EPS) of NZ$35.26 an increase over its 2024 EPS that were of NZ$23.29.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23-22.79%
2025NZ$35.2651.44%
2024NZ$23.29-369.77%
2023NZ-$8.63-60.46%
2022NZ-$21.8363.33%
2021NZ-$13.37-40.37%
2020NZ-$22.42183.47%
2019NZ-$7.91123.09%
2018NZ-$3.5454.93%
2017NZ-$2.2914.07%
2016NZ-$2.0113.05%
2015NZ-$1.77-36.34%
2014NZ-$2.79209.04%
2013NZ-$0.90-33.99%
2012NZ-$1.37185.59%
2011NZ-$0.48